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Purpose: As the elderly population increases, a growing number of patients have lower urinary tract symptom (LUTS)/benign 
prostatic hyperplasia (BPH). The aim of this study was to develop decision support formulas and nomograms for the predic-
tion of bladder outlet obstruction (BOO) and for BOO-related surgical decision-making, and to validate them in patients with 
LUTS/BPH.
Methods: Patient with LUTS/BPH between October 2004 and May 2014 were enrolled as a development cohort. The available 
variables included age, International Prostate Symptom Score, free uroflowmetry, postvoid residual volume, total prostate vol-
ume, and the results of a pressure-flow study. A causal Bayesian network analysis was used to identify relevant parameters. Us-
ing multivariate logistic regression analysis, formulas were developed to calculate the probabilities of having BOO and requir-
ing prostatic surgery. Patients between June 2014 and December 2015 were prospectively enrolled for internal validation. Re-
ceiver operating characteristic curve analysis, calibration plots, and decision curve analysis were performed.
Results: A total of 1,179 male patients with LUTS/BPH, with a mean age of 66.1 years, were included as a development cohort. 
Another 253 patients were enrolled as an internal validation cohort. Using multivariate logistic regression analysis, 2 and 4 
formulas were established to estimate the probabilities of having BOO and requiring prostatic surgery, respectively. Our analy-
sis of the predictive accuracy of the model revealed area under the curve values of 0.82 for BOO and 0.87 for prostatic surgery. 
The sensitivity and specificity were 53.6% and 87.0% for BOO, and 91.6% and 50.0% for prostatic surgery, respectively. The 
calibration plot indicated that these prediction models showed a good correspondence. In addition, the decision curve analy-
sis showed a high net benefit across the entire spectrum of probability thresholds.
Conclusions: We established nomograms for the prediction of BOO and BOO-related prostatic surgery in patients with 
LUTS/BPH. Internal validation of the nomograms demonstrated that they predicted both having BOO and requiring prostat-
ic surgery very well.
Keywords: Prostatic Hyperplasia; Decision Support Systems, Clinical; Nomograms; Urinary Bladder Neck Obstruction; Pros-
tatectomy
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INTRODUCTION
As the elderly population increases, a growing number of pa-
tients have lower urinary tract symptom (LUTS)/benign pros-
tatic hyperplasia (BPH) [1]. The treatment of BPH includes 
watchful waiting, medical management, and surgical treatment. 
Medication has been widely used in patients with mild to bor-
derline symptoms. The guidelines of the European Urological 
Association and the American Urological Association indicate 
that surgical treatment is necessary when patients have urinary 
retention, renal insufficiency, recurrent urinary tract infections, 
bladder stone, or gross hematuria due to an enlarged prostate 
[2,3]. 
 However, most patients with LUTS/BPH we encounter in 
clinical practice do not fall under the above absolute indica-
tions. Surgery is additionally needed when patients do not ex-
perience adequate relief from LUTS with conservative or medi-
cal treatment [2]. This relative surgical indication usually re-
flects the subjective judgment of the surgeon, and/or patients’ 
degree of compliance and preference for surgery [3]. In real 
clinical situations, the decision is not simple. It is sometimes 
difficult to make a clear decision about the treatment of those 
who do not have an absolute indication for prostatic surgery. 
Therefore, the development of objective therapeutic guidance is 
necessary.
 LUTS/BPH is a progressive disease that can eventually cause 
irreversible changes in bladder function, especially if bladder 
outlet obstruction (BOO) is already present. Therefore, when 
BOO is evident in patients with bothersome LUTS, surgical 
treatment should be considered. A pressure-flow study (PFS) is 
currently considered the gold standard for diagnosing BOO; 
however, it is an invasive and time-consuming procedure. Non-
invasive or less invasive modalities have not been fully validated 
for clinical use.
 At the Seoul National University Hospital (SNUH), we have 
a large urodynamic study database that has been constructed 
over the last 13 years. Based on this, we aimed to develop deci-
sion support formulas and nomograms predicting the proba-
bilities of having BOO and requiring BOO-related prostatic 
surgery in patients with LUTS/BPH. We also attempted to vali-
date these formulas and nomograms in a prospective cohort of 
patients with LUTS/BPH.
MATERIALS AND METHODS
Patients and Evaluation
We have constructed a urodynamic study database at SNUH 
starting in 2004. From this large database consisting of 11,437 
consecutive patients between October 2004 and May 2014, 
LUTS/BPH patients aged 45 or over were extracted. LUTS in-
volving the following conditions were excluded to construct 
pure a LUTS/BPH patient dataset (the development cohort): 
urethral stricture, bladder stone, genitourinary infection or in-
flammation, genitourinary malignancy, genitourinary radia-
tion, urinary diversion, or neurogenic bladder. We additionally 
excluded 309 patients who had previously undergone prostatic 
surgery. We ultimately retrieved 2,732 patients with pure LUTS/
BPH.
 Clinical parameters were obtained in routine, real clinical 
practice settings, with careful history-taking, a physical exami-
nation including a digital rectal examination, the International 
Prostate Symptom Score (IPSS), laboratory tests including uri-
nalysis and serum prostate-specific antigen (PSA) levels, and a 
voiding diary. After free uroflowmetry (UFM), postvoid residu-
al (PVR) volume was measured using an ultrasound bladder 
scanner (BVI-3000 BladderScan, Verathon, WA, USA or Bio-
Con-500, Mcube Technology, Seoul, Korea) in the supine posi-
tion. The IPSS storage subscore was the sum of IPSS questions 
2, 4, and 7, and the voiding subscore was the sum of IPSS ques-
tions 1, 3, 5, and 6. UFM results were accepted only when the 
voided volume was over 120 mL. Prostatic biopsies were per-
formed to exclude cancer when the serum PSA level was elevat-
ed (>4 ng/mL) or when a digital rectal examination was suspi-
cious for prostate cancer. Total prostate volume (TPV) was cal-
culated using the prolate ellipsoid formula (π/6 × height × 
width×length) based on transrectal ultrasonography (TRUS) 
measurements in 3 dimensions. A PFS to determine whether 
BOO was present was performed in our Urodynamic Suite us-
ing a multichannel urodynamic machine (UD-2000 or Solar, 
MMS, Enschede, the Netherlands), as previously described [4]. 
We strictly followed the International Continence Society stan-
dards in performing urodynamic studies [5]. BOO was defined 
as a BOO index ≥40; the BOO index was determined by the 
formula of detrusor pressure at the maximal flow rate (PdetQ-
max) –2 ×maximal flow rate (Qmax) in the PFS [6]. Of the 
2,732 patients, any patient who was missing 1 or more of the 
following clinical variables was excluded: IPSS, voided volume 
for UFM of at least 120 mL, PVR volume, TRUS-measured 
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TPV, PFS, and information regarding surgery.
 The electronic medical records of all patients were thorough-
ly reviewed to exclude any patients who fulfilled the exclusion 
criteria. Ultimately, a database of pure LUTS/BPH patients with 
complete clinical variables was obtained as the development 
cohort for developing both formulas (for having BOO and for 
undergoing prostatic surgery). The need for prostatic surgery 
was based on the clinical judgment of urologists, not the actual 
performance of surgery. Therefore, if patients did not agree to 
undergo prostatic surgery when clinicians recommended it, we 
still classified these patients as requiring prostatic surgery. The 
prostatic surgery techniques for LUTS/BPH included open 
prostatectomy, transurethral resection of the prostate, transure-
thral incision of the prostate, laser photoselective vaporization 
of the prostate, and holmium laser enucleation of the prostate.
 Separately from the development cohort, we prospectively 
enrolled consecutive LUTS/BPH patients with the same inclu-
sion and exclusion criteria between June 2014 and December 
2015 at SNUH to construct an internal validation cohort. This 
study was approved by the Institutional Review Board of SNUH 
(approval number: H-1406-119-591).
Statistical Analysis
Causal Bayesian network (CBN) analysis was performed to 
identify clinically relevant variables related to BOO and pros-
tatic surgery. Using ovals to represent variables and arcs for 
their plausible causal relationships, CBN visually presents first- 
and second-degree relationships among the nomograms of 
clinical parameters for BOO and prostatic surgery. We used 
Banjo ver. 2.2.0 (Duke University, Durham, NC, USA; non-
commercially available at https://users.cs.duke.edu/~amink/
software/banjo/) [7,8] to analyze the collected data and to de-
velop the best-fitting CBN model. The CBN model identified 
the most relevant clinical variables and predicted the probabili-
ty of a subject having BOO and the probability of a subject re-
quiring prostatic surgery. We additionally used multivariate lo-
gistic regression analysis incorporating the relevant clinical 
variables to build formulas to calculate the probabilities of hav-
ing BOO and requiring prostatic surgery.  
 To evaluate the predictions based on the calculated probabil-
ities, receiver operating characteristic curve analysis was applied 
to calculate the area under the curve (AUC) of the prediction, 
with AUCs of 0.70–0.79 considered to indicate acceptable dis-
crimination, 0.80–0.89 to indicate excellent discrimination, and 
>0.90 to indicate outstanding discrimination [9]. To assess cali-
bration, calibration plots were generated to visualize the agree-
ment between the predicted probability of both having BOO 
and requiring prostatic surgery, and the actual fact of both hav-
ing BOO and undergoing prostatic surgery. Decision curve 
analysis was used to assess the clinical usefulness of each pre-
diction model by quantifying the net benefits achieved by mak-
ing decisions at each probability threshold [10]. Sensitivity, 
specificity, the positive predictive value, and the negative pre-
dictive value were obtained and reported. 
 Two-sided P-values<0.05 were considered to indicate statis-
tical significance. All statistical analyses were performed using 
R 3.3.1 (R Foundation for Statistical Computing, Vienna, Aus-
tria; http://www.R-project.org), and the IBM SPSS Statistics ver. 
23.0 (IBM Co., Armonk, NY, USA).
RESULTS
Patient Demographics
A total of 1,179 patients with LUTS/BPH were included as the 
development cohort for the prediction models. The mean age 
of the patients was 66.1 years. The average TPV was 48.2 mL, 
and the mean BOO index was 33.4 (Table 1). Among the pa-
tients who underwent a PFS for LUTS/BPH, prostatic surgery 
was recommended to 746 patients (63.3%) by urologists. How-
ever, 616 patients (52.2%) were found to have actually under-
gone surgery.
Development of a Prediction Model
Several clinically important parameters used for establishing 
the formulas were selected using a CBN analysis. TPV, Qmax, 
and PVR had a first-degree relationship with BOO. PSA and 
transitional zone volume (TZV) of the prostate had a second-
degree relationship with BOO. In addition, TPV and the BOO 
index had a first-degree relationship with prostatic surgery. The 
IPSS voiding subscore, PVR, Qmax of free flow, PSA, and TZV 
had a second-degree relationship with prostatic surgery (Fig. 1). 
Serum PSA level was significantly related to TPV; therefore, it 
was omitted from the final parameters, and the rest of the pa-
rameters were included to develop the formula.
 In the multivariate logistic regression analysis, age, Qmax, 
PVR, and TPV were identified as independently significant 
variables associated with BOO (Table 2). In addition, age, 
Qmax, PVR, TPV, the IPSS voiding subscore, the IPSS storage 
subscore, the IPSS quality of life, and the BOO index were iden-
tified as independently significant variables associated with re-
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Table 1. Characteristics and comparison of patients’ demographic variables between the development cohort and the internal valida-
tion cohort    
Characteristic Development (n=1,179) Internal validation (n=253) P-value
Age (yr) 66.1±7.2 69.1±6.8 <0.001
IPSS
   Voiding subscore
   Storage subscore
   Quality of life
17.8±7.8
10.6±5.5
7.0±3.4
3.9±1.1
17.3±8.0
10.6±5.5
7.1±3.4
3.8±1.3
0.244
0.200
0.539
0.293
Total prostate volume (mL) 48.2±27.5 60.7±31.0 <0.001
Transitional zone volume (mL) 23.7±21.4 37.3±38.7 <0.001
Prostate-specific antigen (ng/mL) 2.63±3.41 3.4±6.7 0.160
Uroflowmetry parameters
   Maximal flow rate (mL/sec)
   Voided volume (mL)
   Postvoid residual volume (mL)
  
12.0±5.1
234.5±106.1
57.1±79.2
  
11.7±4.7
226.8±91.2
63.9±31.0
  
0.296
0.782
0.199
Urodynamic study parameter
   First desire (mL)
   Normal desire (mL)
   Strong desire (mL)
   MCC (mL)
   IDC
   PdetQmax
   Maximal flow rate of PFS
   BOOI
   BCI
  
205.4±91.5
287.1±109.5
373.3±108.3
375.3±117.6
298 (25.3)
52.5±20.7
9.1±4.6
33.4±23.6
98.1±27.1
  
191.5±94.9
206.5±97.5
372.3±108.9
328.0±145.3
115 (45.5)
54.1±22.4
7.9±3.7
38.9±25.1
93.9±30.5
  
0.647
<0.001
0.835
<0.001
<0.001
0.213
0.002
0.001
0.123
Decision to perform prostatic surgery 746 (63.3) 201 (79.4) <0.001
Actually underwent prostatic surgery 616 (52.2) 179 (70.8) <0.001
Values are presented as mean±standard deviation or number (%).     
IPSS, International Prostate Symptom Score; voiding subscore, sum of questions 1, 3, 5, and 6 of the IPSS; storage subscore, sum of questions 2, 4, 
and 7 of the IPSS; quality of life, score of question 8 of the IPSS; MCC, maximal cystometric capacity; IDC, involuntary detrusor contraction; PdetQ-
max, detrusor pressure at the maximal flow rate; PFS, pressure-flow study; BOOI, bladder outlet obstruction index; BCI, bladder contractility index.
Fig. 1. A causal Bayesian network model for bladder outlet obstruction (A) and surgical decision-making (B), indicating the parameters 
that directly influenced the presence of urodynamically confirmed bladder outlet obstruction and the physician’s surgical decision. These 
models were established using Banjo version 2.2.0 (Duke University, Durham, NC, USA). TZV, transitional zone volume; PSA, prostate-
specific antigen; Qmax, maximal flow rate; PVR, postvoid residual volume; TPV, total prostate volume; BOO, bladder outlet obstruction; 
IPSS, International Prostate Symptom Score; IPSS voiding subscore, sum of questions 1, 3, 5, and 6 of the IPSS; IPSS storage subscore, 
sum of questions 2, 4, and 7 of the IPSS; IPSS quality of life, question 8 of the IPSS; BOOI, bladder outlet obstruction index.
A
Age
TZV PSA
TPVPVRQmax
BOO
B
Age
TZV PSA
TPVPVR
Qmax
IPSS storage 
IPSS voiding 
IPSS quality 
of life
IPSS Total
Surgical decision
IPSS 7 IPSS 4
BOOI
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quiring prostatic surgery (Table 3). These variables were used to 
build the prediction model for both BOO and prostatic surgery. 
Two formulas were developed to estimate the probability of 
having BOO even if TPV is not available. We prepared a total 
of 4 formulas to assist in surgical decision-making for each of 
the following situations: all variables present, no TPV, no BOO 
index, and neither TPV nor BOO index. Using these formulas, 
nomograms for both BOO and prostatic surgery were generat-
ed using the verified predictors by weighting the relative contri-
bution of the selected variables. We adopted the calculated 
probability of having BOO to calculate the probability of pros-
tatic surgery if a PFS was not performed. The nomograms are 
shown in Fig. 2. When the prediction model yielded a calculat-
ed probability of having BOO or requiring prostatic surgery of 
50% or more, it was considered that BOO was present or sur-
gery was necessary.
 
Internal Validation
A total of 253 male patients with LUTS/BPH were enrolled as 
an internal validation cohort. There were no significant differ-
ences in the IPSS and UFM parameters between the internal 
validation cohort and the development cohort. However, the 
mean values of age, TPV, and the BOO index were greater in 
the internal validation cohort than in the development cohort 
(Table 1).
 In the internal validation cohort, the prediction model was 
found to have an AUC of 0.816 (95% confidence interval [CI], 
0.764–0.868) for BOO and 0.866 (95% CI, 0.819–0.914) for the 
need for surgery (Fig. 3A, C). The sensitivity, specificity, posi-
tive predictive value, and negative predictive value were 53.6%, 
87.0%, 76.6%, and 70.2% for BOO, and 91.6%, 50%, 81.6%, and 
71.2% for prostatic surgery, respectively. The calibration plot 
showed that these prediction models showed a good corre-
spondence between the predicted probabilities of BOO and the 
actual rate of urodynamically confirmed BOO (Fig. 3B). In ad-
dition, the decision curve showed a high net benefit across the 
entire spectrum of probability thresholds (Fig. 3C). Regarding 
the need for prostatic surgery, the calibration plot and the deci-
Table 2. Multivariate logistic regression models for the probability of bladder outlet obstruction     
Variable
All No TPV
P-value OR 95% CI P-value OR 95% CI
Age 0.78 0.997 0.978–1.017 0.067 1.017 0.999–1.035
Qmax <0.001 0.904 0.874–0.935 <0.001 0.905 0.877–0.933
PVR <0.001 1.002 1.002–1.006 <0.001 1.005 1.003–1.007
TPV <0.001 1.042 1.035–1.050 - - -
OR, odds ratio; CI, confidence interval; Qmax, maximal flow rate; PVR, postvoid residual volume; TPV, total prostate volume.   
Table 3. Multivariate logistic regression models for the probability of requiring prostatic surgery     
Variable
All No TPV No BOOI Neither TPV nor BOOI
P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI
Age 0.006 1.029 1.008–1.051 0.009 1.027 1.007–1.048 <0.001 1.045 1.025–1.066 <0.001 1.045 1.026–1.064
Qmax <0.001 0.940 0.911–0.969 <0.001 0.911 0.884–0.939 <0.001 0.950 0.924–0.977 <0.001 0.910 0.885–0.935
PVR 0.271 1.001 0.999–1.004 0.047 1.002 1.000–1.004 0.097 1.002 1.000–1.004 0.001 1.004 1.002–1.006
IPSS
   Voiding subscore <0.001 1.065 1.032–1.099 <0.001 1.064 1.032–1.097 <0.001 1.056 1.025–1.088 0.001 1.050 1.021–1.079
   Storage subscore  0.002 0.924 0.879–0.972 0.013 0.940 0.894–0.987 <0.001 0.917 0.874–0.962 0.006 0.938 0.897–0.981
   Quality of life 0.002 1.265 1.088–1.471 0.007 1.226 1.059–1.419 0.009 1.205 1.048–1.386 0.033 1.152 1.011–1.313
TPV <0.001 1.050 1.039–1.061 <0.001 1.060 1.050–1.070 - - - - - -
BOOI <0.001 1.031 1.022–1.040 - - - <0.001 1.045 1.036–1.053 - - -
TPV, total prostate volume; BOOI, bladder outlet obstruction index; OR, odds ratio; CI, confidence interval; Qmax, maximal flow rate; PVR, post-
void residual volume; IPSS, International Prostate Symptom Score; voiding subscore, sum of questions 1, 3, 5, and 6 of the IPSS; storage subscore, 
sum of questions 2, 4, and 7 of the IPSS; quality of life, score of question 8 of the IPSS.      
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Fig. 2. Nomograms predicting urodynamically confirmed BOO and the need for prostatic surgery: (A) for BOO with all parameters, 
(B) for BOO without the total prostate volume, (C) for prostatic surgery with all parameters. (Continued to the next page)
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Fig. 2. (Continued) (D) for prostatic surgery without the BOO index, (E) for prostatic surgery without the total prostate volume, (F) 
for prostatic surgery without the BOO index and total prostate volume. BOO, bladder outlet obstruction; Qmax, maximal flow rate; 
PVR, postvoid residual volume; TPV, total prostate volume; IPSS, International Prostate Symptom Score; IPSS voiding subcore, sum 
of questions 1, 3, 5, and 6 of the IPSS; IPSS storage subscore, sum of questions 2, 4, and 7 of the IPSS; IPSS quality of life, score of ques-
tion 8 of the IPSS; BOOI, bladder outlet obstruction index.
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sion curve likewise showed a good correspondence and a high 
net benefit (Fig. 3E, F).
 
DISCUSSION
We conducted this study using a large database of urodynamic 
studies to develop formulas to predict BOO and the need for 
prostatic surgery. These formulas were calculated based on the 
urodynamic evidence of BOO. We developed 4 formulas, some 
of which can be used even when 1 or 2 parameters are not 
available. To the best of our knowledge, this is the first study of 
the development of a BOO-based decision-support prediction 
model for prostatic surgery in patients with LUTS/BPH. 
 Histologically, BPH corresponds to a proliferation of the 
stromal and epithelial cells in the prostate with aging. However, 
clinically, it is a heterogeneous condition composed of different 
aspects of LUTS, benign enlargement of the prostate, and func-
tional BOO. It is well known that there are poor correlations 
among patients in terms of LUTS, BOO, and prostate volume 
[11]. Although a patient’s symptom severity or quality of life is 
important, these subjective factors are not absolutely reflective 
of objectively measurable parameters. For example, patients 
with detrusor underactivity without either prostate enlarge-
ment or BOO can have significant symptoms and bother. 
Therefore, a surgical decision based simply on the prostate vol-
ume or subjective LUTS might be inappropriate. 
Fig. 3. Internal validation of the nomogram predicting urodynamic bladder outlet obstruction and prostatic surgery. (A) Receiver 
operating characteristic (ROC) curve of the nomogram for bladder outlet obstruction; the orange line indicates the nomogram with 
all parameters, and the green line indicates the nomogram without the bladder outlet obstruction (BOO) index. (B) A calibration plot 
to show the predicted probability of bladder outlet obstruction. (C) Decision curve analysis revealed that the prediction model for 
bladder outlet obstruction provided a superior net benefit. (D) ROC curve of the nomogram for prostatic surgery; the orange line in-
dicates the nomogram with all parameters, the black line indicates the nomogram without the BOO index, the green line indicates 
the nomogram without total prostate volume, and the black dotted line indicates the nomogram without the BOO index and total 
prostate volume. (E) A calibration plot to show the predicted probability of prostatic surgery. (F) Decision curve analysis revealed that 
the prediction model for the need for prostatic surgery provided a superior net benefit.
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 In patients with marginal clinical situations, urodynamically 
confirmed BOO can be used as an important guide in surgical 
decision-making. Urodynamic studies have been advocated as 
a useful predictor of the success of surgery, and this has been 
encouraged by international guidance [12,13]. Our meta-analy-
sis likewise showed a significant association between urody-
namically confirmed BOO and greater improvements in all 
treatment outcome parameters. Preoperative urodynamic stud-
ies may add insight into postoperative outcomes after the surgi-
cal treatment of BPH [14]. BOO is significantly associated with 
both functional and morphological alterations of the urinary 
bladder. Animal experiments have demonstrated that chronic 
BOO can cause repeated bladder ischemia/reperfusion injuries, 
ultimately resulting in partial denervation of the bladder 
[15,16]. Such oxidative stress is responsible for bladder hyper-
activity in moderate cases or detrusor underactivity, if it is pro-
longed [17,18]. Abundant clinical evidence has shown that 
BOO is significantly associated with functional changes in the 
urinary bladder. We analyzed the clinical and urodynamic 
characteristics of 429 elderly men with LUTS/BPH according 
to a urodynamic study. Patients with BOO had a significantly 
higher rate of involuntary detrusor contraction and poor com-
pliance compared to the patients without BOO [19]. Therefore, 
it is functional BOO that directly causes undesirable conse-
quences, such as overactive bladder or underactive bladder. In 
addition, classic findings have also shown that urodynamically 
confirmed BOO is closely associated with morphological 
changes of the urinary bladder. A significant correlation was 
found between bladder trabeculation and the grade of BOO in 
old men with presumptive LUTS/BPH [20,21]. BOO con-
firmed through a urodynamic study was also closely related 
with radiologically demonstrated trabeculation [21]. Therefore, 
bladder dysfunction secondary to BOO must be considered in 
the management of male patients with LUTS. The surgical 
treatment of patients who satisfy the absolute indications for 
surgery is often too late. This means that the conditions might 
be irreversible, in functional or morphological aspects, even af-
ter surgical relief.
 In patients who do not meet the absolute indications for sur-
gery, patient selection for surgery is often not easy. This deci-
sion may depend on the degree of bother of the LUTS, prostate 
volume, comorbidities, a patient’s personal preferences, the fi-
nancial status of the patient, the patient’s willingness to accept 
potential surgery-associated complications, the experience of 
the surgeon, and the availability of a specific surgical armamen-
tarium. In our institution, the decision to perform surgery in 
patients who did not meet the absolute indications was made 
more based on the presence of urodynamically confirmed 
BOO than on patient requests or prostate volume. We do not 
commonly recommend surgery to patients when they do not 
have significant BOO, even though the patient may have an en-
larged prostate. PFS is considered as the gold standard for diag-
nosing BOO. Unfortunately, none of the noninvasive tests for 
diagnosing BOO in men with LUTS can currently be recom-
mended as an alternative to a PFS [22]. However, urodynamic 
studies are not recommended for routine clinical use due to 
their invasiveness, expense, time-consuming nature, and tech-
nical challenges [23]. For this reason, we thought that a predic-
tion model for BOO-based surgical decision-making without 
performing PFS would be very important. This study is an ex-
tension of our previous clinical studies involving BOO in pa-
tients with LUTS/BPH. We have performed several clinical 
studies using data that we have accumulated over the last 15 
years. We sought to identify noninvasive parameters for pre-
dicting BOO using our clinical data, and found that Qmax 
played a significant role in predicting BOO in Korean men with 
LUTS [19]. More recently, we also analyzed data from 1,381 pa-
tients with BPH using CBN analysis and found that TPV, 
Qmax, and PVR were independent predictive parameters of 
urodynamically confirmed BOO [8].
 One of the advantages of our urodynamic data is that the 
urodynamic studies were performed by the same investigators 
in a single center using the same practice protocol since 2002 
when the International Continence Society standardization was 
published [5]. In our institution, the prevalence of BOO among 
patients with LUTS/BPH is relatively high. We have a high 
number of patients who potentially need prostate surgery, as 
our hospital is a tertiary referral center with a heavy clinical vol-
ume. In this dataset, patients with an absolute indication for 
prostatic surgery were also included. This means that the clini-
cal parameters of these patients were incorporated in these for-
mulas. If patients did not agree to undergo surgery when the 
clinician recommended it, we still classified these patients as re-
quiring prostatic surgery. The category of requiring surgery in 
this study solely reflects the decisions made by urologists.
 A major limitation of our study is that only a few surgeons 
were involved in surgical decision-making in the BPH popula-
tion. This might also have caused some bias in the surgical deci-
sions, making these results not generalizable. However, the 
need for surgery determined by the surgeons is not essentially 
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different from what would be expected based on textbook 
guidelines, since they followed the clinical guidelines published 
by the American Urological Association or the European Uro-
logical Association in their routine clinical practice [2,3]. Addi-
tionally, the need for surgery was not merely judged by the pa-
tient’s request, but by considering the entire clinical situation of 
the patients, including more objective parameters such as uro-
dynamically confirmed BOO. We believe that surgical decision-
making in real clinical situations for LUTS/BPH patients whose 
conditions do not satisfy the absolute indications for surgery 
should be primarily based on the presence of functional ob-
struction. The purpose of surgery in patients with LUTS/BPH 
is to relieve conditions such as acute urinary retention, gross 
hematuria of prostatic origin, associated bladder stones, or hy-
dronephrosis in patients who satisfy the absolute surgical indi-
cations for BPH. However, symptom improvement and overall 
patient satisfaction after prostate surgery are primary goals in 
patients who do not satisfy the absolute surgical indications. 
Based on our unpublished data, we found that the overall pa-
tient satisfaction after prostatectomy in patients with LUTS/
BPH was very high (over 90%), with the current surgical deci-
sion-making process being based mainly on urodynamically 
confirmed BOO. We believe that our current process of select-
ing patients for surgery is reasonably justified.
 We expect that this urodynamic BOO-based prediction 
model will be of great help in actual clinical practice. We believe 
that further validation in other ethnic populations is necessary, 
as this formula is based on an Asian population. Additionally, 
more research into subjective satisfaction and symptom im-
provement in patients who undergo prostatic surgery based on 
this nomogram is needed to justify our work.
 In conclusion, we established nomograms for the prediction 
of BOO and the need for BOO-related surgery in patients with 
LUTS/BPH. Internal validation of the nomograms demonstrat-
ed that these nomograms predicted both BOO and requiring 
prostatic surgery very well. We hope that these BPH probability 
models will help clinicians to better select LUTS/BPH patients 
requiring surgical treatment.
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